SBIR/STTR Research Award
Improved Formulations to Enhance Bio-availability for Antisense Therapeutics
Award amount
$70,000Program and phase
SBIR · Phase IAward year
2010Award details
- Awarding agency
- Department of Defense
- Branch
- Office for Chemical and Biological Defense
- Recipient company
- LNKCHEMSOLUTIONS
- Proposal award date
- 2010-05-17
- Contract end date
- 2010-11-16
- UEI
- Not reported
- Solicitation number
- 2010.1
- Topic code
- CBD10-102
Research abstract
In general, many biological and chemical agents affect the lungs directly or indirectly, even if the respiratory system is not the primary target organ of a military or terrorist attack. Both in the case of military and civilian attacks the lung can be one of the first organs affected by a chemical or biological agent. LNK Chemsolutions (LNK) with expertise in nanoparticle formulations and the University of Illinois Chicago with expertise in Acute Lung Injury (ALI) molecular biology and treatment modality development have teamed up to develop novel oral and inhalation formulation of targeted nanoparticles (NPs) containing siRNA and/or miRNA to improve the treatment of ALI unobtainable with current delivery systems.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device
- Multifunctional Antisense Therapeutics Nanocarrier and Inhalation Device